COVID-19 mRNA Vaccine-Associated Myocarditis Presenting as STEMI in a 48-Year-Old Male.

Autor: Dlewati M; Division of Internal Medicine, Memorial Healthcare System, Hollywood, Florida, USA., Park K; Division of Internal Medicine, Memorial Healthcare System, Hollywood, Florida, USA., Rawat S; Division of Internal Medicine, Memorial Healthcare System, Hollywood, Florida, USA., Conte J; Division of Internal Medicine, Memorial Healthcare System, Hollywood, Florida, USA.; Division of Cardiology, Memorial Healthcare System, Hollywood, Florida, USA., Bhadha K; Division of Internal Medicine, Memorial Healthcare System, Hollywood, Florida, USA.; Division of Cardiology, Memorial Healthcare System, Hollywood, Florida, USA.
Jazyk: angličtina
Zdroj: Case reports in cardiology [Case Rep Cardiol] 2022 Apr 15; Vol. 2022, pp. 2284530. Date of Electronic Publication: 2022 Apr 15 (Print Publication: 2022).
DOI: 10.1155/2022/2284530
Abstrakt: Myocarditis has been recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccinations. Young adult and adolescent males < 30 years of age are the most commonly affected group, with decreased incidence with older age. This is a case of a 48-year-old male who presented with chest pain and EKG findings of STEMI shortly after receiving the second dose of the Moderna COVID-19 mRNA vaccine. Emergent left heart catheterization revealed normal coronaries. Subsequently, the patient had rapid resolution of his symptoms and improvement in serum markers. The exact etiology factors to this new and rare phenomenon are yet to be fully understood. This patient did have a history of previous viral myocarditis 7 years ago; however, it remains unclear if this could be a predisposing factor to the development of mRNA vaccine-associated myocarditis.
Competing Interests: The authors declare that they have no conflicts of interest
(Copyright © 2022 Mohammad Dlewati et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje